Fate Therapeutics (NASDAQ:FATE) Analyst Rating Consensus

Fate Therapeutics (NASDAQ:FATE) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.2 by 5 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating.

Other Equity analysts have also commented on the company shares. BMO Capital initiates coverage on Fate Therapeutics (NASDAQ:FATE). In the latest research report, BMO Capital announces the target price to $4 per share. According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on April 12, 2016.

Fate Therapeutics (NASDAQ:FATE): According to 4 Analysts, The short term target price has been estimated at $ 5.The target price could deviate by a maximum of $2 from the forecast price. In the near term, the target price could hit a high of $8 and a low of $ 4.

Fate Therapeutics (NASDAQ:FATE) witnessed a decline in the market cap on Tuesday as its shares dropped 5.5% or 0.11 points. After the session commenced at $2.1, the stock reached the higher end at $2.1 while it hit a low of $1.78. With the volume soaring to 1,038,471 shares, the last trade was called at $1.89. The company has a 52-week high of $8.37. The company has a market cap of $55 million and there are 28,864,054 shares in outstanding. The 52-week low of the share price is $1.46.

Shares of Fate Therapeutics, Inc. rose by 8.62% in the last five trading days and 25.17% for the last 4 weeks. Fate Therapeutics, Inc. has dropped 5.03% during the last 3-month period . Year-to-Date the stock performance stands at -43.92%.

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Companys development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)), which targets Hematologic, Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II, Phase Ib and Phase Ib, respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB), which is for Hematologic and Malignancies therapeutic area, and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells, human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.